2021
Author Response: Cause of Death in Spontaneous Intracerebral Hemorrhage Survivors: Multistate Longitudinal Study
Kuohn L, Sheth K. Author Response: Cause of Death in Spontaneous Intracerebral Hemorrhage Survivors: Multistate Longitudinal Study. Neurology 2021, 97: 149-149. DOI: 10.1212/wnl.0000000000012283.Peer-Reviewed Original ResearchIntracerebral hemorrhage survivorsSpontaneous intracerebral hemorrhage survivorsAdjusted multinomial logistic regression modelIndependent risk factorInfection-related mortalityBurden of disabilityInfection-related deathsInfection-related morbidityUrinary tract infectionOdds of deathLong-term outcomesCause of deathLogistic regression modelsDeath overallICH survivorsAspiration pneumoniaMultinomial logistic regression modelsTract infectionsChronic hospitalizationRisk factorsDiabetesPotential associationClostridium difficileInfectionOlder ageStatin exposure and risk of cancer in people with and without HIV infection.
Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, Gibert C, Justice AC, Tate JP. Statin exposure and risk of cancer in people with and without HIV infection. AIDS 2021, 35: 325-334. PMID: 33181533, PMCID: PMC7775280, DOI: 10.1097/qad.0000000000002748.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyStatin useStatin exposureHazard ratioCancer riskLower riskPropensity score-matched cohortCox regression hazard ratiosAging Cohort StudyAnti-inflammatory effectsRegression hazard ratiosNon-Hodgkin lymphomaConfidence intervalsCancer registry linkagePropensity score-matched sampleRisk of cancerDeath overallUninfected patientsCohort studyIncident cancerRegistry linkageHIV infectionHIV statusStatin initiatorsUninfected persons
2020
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Müller V, Carey L, McGoldrick S, An G, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1005-1005. DOI: 10.1200/jco.2020.38.15_suppl.1005.Peer-Reviewed Original ResearchMetastatic breast cancerProgression-free survivalObjective response rateBrain metastasesOverall survivalCNS-PFSControl armSecond progressionEfficacy analysisBrain progressionLocal treatmentBreast cancerProlongation of PFSMedian progression-free survivalExploratory efficacy analysesMedian CNS-PFSMedian overall survivalBaseline brain MRIHER2 kinase inhibitorDeath overallRECIST 1.1Study therapyFree survivalInvestigator's evaluationIC disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply